Assessment of lymph nodes and prostate status with early dynamic curves PET/CT 18F-choline in prostate cancer

被引:2
|
作者
Mathieu, C. [1 ]
Ferrer, L. [2 ,3 ]
Carlier, T. [2 ,4 ]
Colombie, M. [1 ]
Rusu, D. [1 ]
Kraeber-Bodere, F. [1 ,2 ,4 ]
Campion, L. [2 ,5 ]
Rousseau, C. [1 ,2 ]
机构
[1] ICO Rene Gauducheau, Serv Med Nucl, F-44805 St Herblain, France
[2] INSERM, CRCNA, UMR 892, CNRS UMR 6299, F-44007 Nantes 1, France
[3] ICO Rene Gauducheau, Serv Phys Med, F-44805 St Herblain, France
[4] CHU Nantes, Serv Med Nucl, F-44093 Nantes, France
[5] ICO Rene Gauducheau, Serv Biostast, F-44805 St Herblain, France
来源
MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE | 2015年 / 39卷 / 02期
关键词
F-18-choline; Prostate cancer; Dynamic curves; Early acquisition; MRI; LOCALIZATION; RELAPSE; RISK;
D O I
10.1016/j.mednuc.2015.01.006
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aim. - Analyse early dynamic F-18-Choline (FCH) PET/CT acquisitions to define lymph nodes and prostate pathological status. Patients and methods. - Retrospective analysis was performed on 39 patients for initial staging (n = 18) or after initial treatment (n = 21). Patients underwent 10 minutes dynamic acquisitions centered on pelvis, after injection of 3-4 MBq/kg of FCH. Whole body images were performed about 1 hour after injection and were acquired on PET/CT GE Discovery LS (GE-LS) or Siemens Biograph mCT (mCT). Maximum SUVaccording to time was measured on lymph nodes and prostate lesions. The status of each lesion was based on histological results or patient follow-up (> 6 months). Results. - The median PSA was 8.46 ng/mL and the median Gleason 3+4. Ninety-two lesions (43 lymph nodes and 49 prostate lesions) were analyzed, including 63 malignant lesions. In early dynamic acquisitions, the maximum SUV was significantly higher, respectively on mCT and GE-LS, in positive lymph nodes (P < 0.001, P = 0.007) and prostate (P = 0.001, P = 0.02). ROC curves showed for lymph nodes acquired on mCT, a trend to better numbers of sensitivity and specificity for early acquisitions, compared with late acquisitions. Conclusion. - Assessment of lymph nodes and prostate pathological status with early dynamic curves PET/CT FCH was interestingly possible in a disease where proofs of malignancy are difficult to obtain. (C) 2015 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:138 / 147
页数:10
相关论文
共 50 条
  • [21] Role of 18F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer
    Chondrogiannis, Sotirios
    Marzola, Maria Cristina
    Ferretti, Alice
    Maffione, Anna Margherita
    Rampin, Lucia
    Grassetto, Gaia
    Nanni, Cristina
    Colletti, Patrick M.
    Rubello, Domenico
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (09) : 1356 - 1364
  • [22] PET imaging in prostate cancer, state of the art: a review of 18F-choline and 11C-choline PET/CT applications
    Castellucci P.
    Ceci F.
    Graziani T.
    Fanti S.
    Clinical and Translational Imaging, 2016, 4 (6) : 449 - 456
  • [23] Role of 18F-Choline PET/CT in guiding biopsy in patients with risen PSA levels and previous negative biopsy for prostate cancer
    Jimenez Londono, G. A.
    Garcia Vicente, A. M.
    Amo-Salas, M.
    Funez Mayorga, F.
    Lopez Guerrero, M. A.
    Talavera Rubio, M. P.
    Gutierrez Martin, P.
    Gonzalez Garcia, B.
    de la Torre Perez, J. A.
    Soriano Castrejon, A. M.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2017, 36 (04): : 241 - 246
  • [24] 18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready?
    Urso, Luca
    Lancia, Federica
    Ortolan, Naima
    Frapoli, Marta
    Rauso, Martina
    Artioli, Paolo
    Cittanti, Corrado
    Uccelli, Licia
    Frassoldati, Antonio
    Evangelista, Laura
    Bartolomei, Mirco
    CLINICAL AND TRANSLATIONAL IMAGING, 2022, 10 (06) : 687 - 695
  • [25] 18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready?
    Luca Urso
    Federica Lancia
    Naima Ortolan
    Marta Frapoli
    Martina Rauso
    Paolo Artioli
    Corrado Cittanti
    Licia Uccelli
    Antonio Frassoldati
    Laura Evangelista
    Mirco Bartolomei
    Clinical and Translational Imaging, 2022, 10 : 687 - 695
  • [26] Recurrent prostate cancer after radical prostatectomy: restaging performance of 18F-choline hybrid PET/MRI
    Achard, Verane
    Lamanna, Giorgio
    Denis, Antoine
    De Perrot, Thomas
    Mainta, Ismini Charis
    Ratib, Osman
    Iselin, Christophe
    Miralbell, Raymond
    Garibotto, Valentina
    Zilli, Thomas
    MEDICAL ONCOLOGY, 2019, 36 (08)
  • [27] Optimization of 18F-Choline PET/CT acquisition in prostate cancer: Preliminary results concerning the length of the acquisition
    Palard-Novello, X.
    Bourguet, P.
    Bourhis, D.
    Le Jeune, F.
    Garin, E.
    Salaun, P. -Y.
    Devillers, A.
    Gambarota, G.
    Querellou, S.
    Saint-Jalmes, H.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2017, 41 (01): : 15 - 20
  • [28] 18F-Choline PET/CT Pitfalls in Image Interpretation An Update on 300 Examined Patients With Prostate Cancer
    Calabria, Ferdinando
    Chiaravalloti, Agostino
    Schillaci, Orazio
    CLINICAL NUCLEAR MEDICINE, 2014, 39 (02) : 122 - 130
  • [29] Accuracy of tumor segmentation from multi-parametric prostate MRI and 18F-choline PET/CT for focal prostate cancer therapy applications
    Piert, Morand
    Shankar, Prasad R.
    Montgomery, Jeffrey
    Kunju, Lakshmi Priya
    Rogers, Virginia
    Siddiqui, Javed
    Rajendiran, Thekkelnaycke
    Hearn, Jason
    George, Arvin
    Shao, Xia
    Davenport, Matthew S.
    EJNMMI RESEARCH, 2018, 8
  • [30] Accuracy of tumor segmentation from multi-parametric prostate MRI and 18F-choline PET/CT for focal prostate cancer therapy applications
    Morand Piert
    Prasad R. Shankar
    Jeffrey Montgomery
    Lakshmi Priya Kunju
    Virginia Rogers
    Javed Siddiqui
    Thekkelnaycke Rajendiran
    Jason Hearn
    Arvin George
    Xia Shao
    Matthew S. Davenport
    EJNMMI Research, 8